GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2019
Epidiolex in the U.S. yielded Q2 net sales of $68.4 million.
Read More
Category: UK Stocks
GW Pharmaceuticals receives positive CHMP opinion for EPIDYOLEX™ (cannabidiol oral solution) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy
If approved cannabidiol oral solution will be the first plant-derived cannabis-based medicine to be approved in Europe for the treatment of any form of epilepsyGW’s.
Read More
GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Period Ending June 30, 2019 and Host Conference Call on August 6, 2019
GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform.
Read More
GW Pharmaceuticals to Present at the 40th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 11th, 2019
Stephen Schultz, GW’s Vice President of Investor Relations, will present at the 40th Annual Goldman Sachs Global Healthcare Conference.
Read More
GW Pharmaceuticals to Present at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 15, 2019
GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas.
Read MoreGET LISTED
